219 related articles for article (PubMed ID: 27234887)
1. Discovery of new [1,4]dioxino[2,3-f]quinazoline-based inhibitors of EGFR including the T790M/L858R mutant.
Qin X; Li Z; Yang L; Liu P; Hu L; Zeng C; Pan Z
Bioorg Med Chem; 2016 Jul; 24(13):2871-2881. PubMed ID: 27234887
[TBL] [Abstract][Full Text] [Related]
2. Novel morpholin-3-one fused quinazoline derivatives as EGFR tyrosine kinase inhibitors.
Qin X; Lv Y; Liu P; Li Z; Hu L; Zeng C; Yang L
Bioorg Med Chem Lett; 2016 Mar; 26(6):1571-1575. PubMed ID: 26879314
[TBL] [Abstract][Full Text] [Related]
3. Design, Synthesis and Biological Evaluation of the Quinazoline Derivatives as L858R/T790M/C797S Triple Mutant Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
Zhang M; Wang Y; Wang J; Liu Z; Shi J; Li M; Zhu Y; Wang S
Chem Pharm Bull (Tokyo); 2020; 68(10):971-980. PubMed ID: 32999149
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of quinazolinones as EGFR inhibitors to overcome EGFR resistance obstacle.
Patel HM; Pawara R; Ansari A; Noolvi M; Surana S
Bioorg Med Chem; 2017 May; 25(10):2713-2723. PubMed ID: 28366268
[TBL] [Abstract][Full Text] [Related]
5. Discovery of 5-(methylthio)pyrimidine derivatives as L858R/T790M mutant selective epidermal growth factor receptor (EGFR) inhibitors.
Xiao Q; Qu R; Gao D; Yan Q; Tong L; Zhang W; Ding J; Xie H; Li Y
Bioorg Med Chem; 2016 Jun; 24(12):2673-80. PubMed ID: 27131639
[TBL] [Abstract][Full Text] [Related]
6. 6,7-Dimorpholinoalkoxy quinazoline derivatives as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells.
Zhang Y; Chen L; Xu H; Li X; Zhao L; Wang W; Li B; Zhang X
Eur J Med Chem; 2018 Mar; 147():77-89. PubMed ID: 29421573
[TBL] [Abstract][Full Text] [Related]
7. Discovery of selective EGFR modulator to inhibit L858R/T790M double mutants bearing a N-9-Diphenyl-9H-purin-2-amine scaffold.
Hu J; Han Y; Wang J; Liu Y; Zhao Y; Liu Y; Gong P
Bioorg Med Chem; 2018 May; 26(8):1810-1822. PubMed ID: 29486953
[TBL] [Abstract][Full Text] [Related]
8. TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells.
Otani H; Yamamoto H; Takaoka M; Sakaguchi M; Soh J; Jida M; Ueno T; Kubo T; Asano H; Tsukuda K; Kiura K; Hatakeyama S; Kawahara E; Naomoto Y; Miyoshi S; Toyooka S
PLoS One; 2015; 10(6):e0129838. PubMed ID: 26090892
[TBL] [Abstract][Full Text] [Related]
9. New acrylamide-substituted quinazoline derivatives with enhanced potency for the treatment of EGFR T790M-mutant non-small-cell lung cancers.
Liu Z; Wang L; Feng M; Yi Y; Zhang W; Liu W; Li L; Liu Z; Li Y; Ma X
Bioorg Chem; 2018 Apr; 77():593-599. PubMed ID: 29482151
[TBL] [Abstract][Full Text] [Related]
10. Discovery of novel 2,4-diarylaminopyrimidine derivatives as potent and selective epidermal growth factor receptor (EGFR) inhibitors against L858R/T790M resistance mutation.
Yan Q; Chen Y; Tang B; Xiao Q; Qu R; Tong L; Liu J; Ding J; Chen Y; Ding N; Tan W; Xie H; Li Y
Eur J Med Chem; 2018 May; 152():298-306. PubMed ID: 29730192
[TBL] [Abstract][Full Text] [Related]
11. Discovery of novel 4-arylamino-quinazoline derivatives as EGFR
Gan W; Wang C; Pan Q; Li Y; Guo Y; Fan D; Peng Y; Rao Z; Xu S; Zheng P; Zhu W
Bioorg Chem; 2022 Oct; 127():105994. PubMed ID: 35792314
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological evaluation of novel 4-anlinoquinazoline derivatives as EGFR inhibitors with the potential to inhibit the gefitinib-resistant nonsmall cell lung cancers.
Wang C; Xu S; Peng L; Zhang B; Zhang H; Hu Y; Zheng P; Zhu W
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):203-217. PubMed ID: 30835140
[TBL] [Abstract][Full Text] [Related]
13. Novel 4-arylaminoquinazoline derivatives with (E)-propen-1-yl moiety as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells.
Chen L; Zhang Y; Liu J; Wang W; Li X; Zhao L; Wang W; Li B
Eur J Med Chem; 2017 Sep; 138():689-697. PubMed ID: 28711703
[TBL] [Abstract][Full Text] [Related]
14. Toward discovery of mutant EGFR inhibitors; Design, synthesis and in vitro biological evaluation of potent 4-arylamino-6-ureido and thioureido-quinazoline derivatives.
Mowafy S; Galanis A; Doctor ZM; Paranal RM; Lasheen DS; Farag NA; Jänne PA; Abouzid KA
Bioorg Med Chem; 2016 Aug; 24(16):3501-12. PubMed ID: 27288180
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and evaluation of A-ring-modified lamellarin N analogues as noncovalent inhibitors of the EGFR T790M/L858R mutant.
Fukuda T; Umeki T; Tokushima K; Xiang G; Yoshida Y; Ishibashi F; Oku Y; Nishiya N; Uehara Y; Iwao M
Bioorg Med Chem; 2017 Dec; 25(24):6563-6580. PubMed ID: 29133033
[TBL] [Abstract][Full Text] [Related]
16. Discovery of pteridin-7(8H)-one-based irreversible inhibitors targeting the epidermal growth factor receptor (EGFR) kinase T790M/L858R mutant.
Zhou W; Liu X; Tu Z; Zhang L; Ku X; Bai F; Zhao Z; Xu Y; Ding K; Li H
J Med Chem; 2013 Oct; 56(20):7821-37. PubMed ID: 24053674
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and in vitro biological evaluation of novel quinazoline derivatives.
Zhang Y; Zhang Y; Liu J; Chen L; Zhao L; Li B; Wang W
Bioorg Med Chem Lett; 2017 Apr; 27(7):1584-1587. PubMed ID: 28238614
[TBL] [Abstract][Full Text] [Related]
18. Novel, selective acrylamide linked quinazolines for the treatment of double mutant EGFR-L858R/T790M Non-Small-Cell lung cancer (NSCLC).
Pawara R; Ahmad I; Nayak D; Wagh S; Wadkar A; Ansari A; Belamkar S; Surana S; Nath Kundu C; Patil C; Patel H
Bioorg Chem; 2021 Oct; 115():105234. PubMed ID: 34399322
[TBL] [Abstract][Full Text] [Related]
19. Structure-activity study of quinazoline derivatives leading to the discovery of potent EGFR-T790M inhibitors.
Zhang L; Yang Y; Zhou H; Zheng Q; Li Y; Zheng S; Zhao S; Chen D; Fan C
Eur J Med Chem; 2015 Sep; 102():445-63. PubMed ID: 26310890
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of 4-aniline quinazoline derivatives conjugated with hydrogen sulfide (H
Zheng YG; Zhang WQ; Meng L; Wu XQ; Zhang L; An L; Li CL; Gao CY; Xu L; Liu Y
Eur J Med Chem; 2020 Sep; 202():112522. PubMed ID: 32619886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
